Literature DB >> 8876128

Site-specific integration by adeno-associated virus.

R M Linden1, P Ward, C Giraud, E Winocour, K I Berns.   

Abstract

Adeno-associated virus (AAV) has attracted considerable interest as a potential vector for gene delivery. Wild-type virus is notable for the lack of association with any human disease and the ability to stably integrate its genome in a site-specific manner in a locus on human chromosome 19 (AAVS1). Use of a functional model system for AAV DNA integration into AAVS1 has allowed us to conclude that the recombination event is directed by cellular DNA sequences. Recombinant junctions isolated from our integration assay were analyzed and showed characteristics similar to those found in latently infected cell lines. The minimal DNA signals within AAVS1 required for targeted integration were identified and shown to contain functional motifs of the viral origin of replication. A replication mediated model of AAV DNA integration is proposed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8876128      PMCID： PMC38050          DOI： 10.1073/pnas.93.21.11288

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  35 in total

1.  ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.

Authors:  R W ATCHISON; B C CASTO; W M HAMMON
Journal:  Science       Date:  1965-08-13       Impact factor: 47.728

2.  Complementation of adeno-associated virus growth with temperature-sensitive mutants of human adenovirus types 12 and 5.

Authors:  H Handa; K Shiroki; H Shimojo
Journal:  J Gen Virol       Date:  1975-11       Impact factor: 3.891

3.  Epidemiology of adenovirus-associated virus infection in a nursery population.

Authors:  N R Blacklow; M D Hoggan; A Z Kapikian; J B Austin; W P Rowe
Journal:  Am J Epidemiol       Date:  1968-11       Impact factor: 4.897

4.  Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics.

Authors:  M D Hoggan; N R Blacklow; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

5.  Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells.

Authors:  K I Berns; T C Pinkerton; G F Thomas; M D Hoggan
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

6.  In vitro replication of adeno-associated virus DNA: enhancement by extracts from adenovirus-infected HeLa cells.

Authors:  P Ward; K I Berns
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants.

Authors:  P L Hermonat; M A Labow; R Wright; K I Berns; N Muzyczka
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

8.  Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells.

Authors:  A K Cheung; M D Hoggan; W W Hauswirth; K I Berns
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

9.  Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication.

Authors:  R M Buller; J E Janik; E D Sebring; J A Rose
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

10.  Gene transfer into the mouse retina mediated by an adeno-associated viral vector.

Authors:  R R Ali; M B Reichel; A J Thrasher; R J Levinsky; C Kinnon; N Kanuga; D M Hunt; S S Bhattacharya
Journal:  Hum Mol Genet       Date:  1996-05       Impact factor: 6.150
View more
  92 in total

1.  Adeno-associated virus site-specifically integrates into a muscle-specific DNA region.

Authors:  N Dutheil; F Shi; T Dupressoir; R M Linden
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  DNA sequence motifs which direct adeno-associated virus site-specific integration in a model system.

Authors:  P Meneses; K I Berns; E Winocour
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 3.  The Gordon Wilson Lecture. From basic virology to human gene therapy.

Authors:  K I Berns
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

4.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 5.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 6.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

7.  Conditional site-specific integration into human chromosome 19 by using a ligand-dependent chimeric adeno-associated virus/Rep protein.

Authors:  D Rinaudo; S Lamartina; G Roscilli; G Ciliberto; C Toniatti
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Cell Cycle-Dependent Expression of Adeno-Associated Virus 2 (AAV2) Rep in Coinfections with Herpes Simplex Virus 1 (HSV-1) Gives Rise to a Mosaic of Cells Replicating either AAV2 or HSV-1.

Authors:  Francesca D Franzoso; Michael Seyffert; Rebecca Vogel; Artur Yakimovich; Bruna de Andrade Pereira; Anita F Meier; Sereina O Sutter; Kurt Tobler; Bernd Vogt; Urs F Greber; Hildegard Büning; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 9.  Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma.

Authors:  Jun Yoshida; Masaaki Mizuno
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

10.  The cellular TATA binding protein is required for rep-dependent replication of a minimal adeno-associated virus type 2 p5 element.

Authors:  Achille François; Mickaël Guilbaud; Rafi Awedikian; Gilliane Chadeuf; Philippe Moullier; Anna Salvetti
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.